Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cause and management of therapy resistance.
Hochhaus A, Schenk T, Erben P, Ernst T, La Rosée P, Müller MC. Hochhaus A, et al. Among authors: schenk t. Best Pract Res Clin Haematol. 2009 Sep;22(3):367-79. doi: 10.1016/j.beha.2009.05.004. Best Pract Res Clin Haematol. 2009. PMID: 19959087 Review.
Harmonization of molecular monitoring of CML therapy in Europe.
Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A. Müller MC, et al. Among authors: schenk t. Leukemia. 2009 Nov;23(11):1957-63. doi: 10.1038/leu.2009.168. Epub 2009 Aug 27. Leukemia. 2009. PMID: 19710700 Review.
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. Schönfeld L, et al. Among authors: schenk t. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. Leukemia. 2022. PMID: 35902731 Free PMC article.
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S, Schenk T, Himsel D, Maier J, Franke GN, Saussele S, Pott C, Andrikovics H, Meggyesi N, Machova-Polakova K, Zizkova H, Jurcek T, Mesanovic S, Zadro R, Gottardi E, Haenig J, Schuld P, Cross NCP, Hochhaus A, Ernst T. Möbius S, et al. Among authors: schenk t. J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650. doi: 10.1007/s00432-019-02910-6. Epub 2019 Apr 2. J Cancer Res Clin Oncol. 2019. PMID: 30941573
267 results